1-(5-Methyl-3,4,5,13-tetrazatetracyclo[13.4.0.02,6.07,12]nonadeca-1(19),2(6),3,7,9,11,15,17-octaen-13-yl)propan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(5-Methyl-3,4,5,13-tetrazatetracyclo[13.4.0.02,6.07,12]nonadeca-1(19),2(6),3,7,9,11,15,17-octaen-13-yl)propan-1-one
• 英文别名: 1-(5-methyl-3,4,5,13-tetrazatetracyclo[13.4.0.02,6.07,12]nonadeca-1(19),2(6),3,7,9,11,15,17-octaen-13-yl)propan-1-one
• 化学式: C₁₉H₁₈N₄O
• 分子量: 318.4
• InChiKey: BUULLCCNPQPIPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  51
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：Mersana Therapeutics, Inc.

  公开号：US20160220696A1

  公开（公告）日：2016-08-04

  Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently an Auristatin compound. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了Auristatin化合物及其共轭物。该共轭物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，该聚合物载体被取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的Auristatin化合物。LD和LP是连接治疗剂和PBRM到聚合物载体的连接物。还公开了用于与PBRM共轭形成聚合物-药物-PBRM共轭物的聚合物支架，以及包含共轭物的组合物，其制备方法以及使用共轭物或其组合物治疗各种疾病的方法。
• HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150306240A1

  公开（公告）日：2015-10-29

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric scaffold having one or more -L D -D, the PBRM being connected to the polymeric scaffold by L p , wherein the polymeric scaffold comprises a linear, branched or cyclic polymer having four or more —OH groups. Each occurrence of D is independently a therapeutic agent having a molecular weight <5 kDa. L D and L p are linkers connecting the therapeutic agent and PBRM to the polymeric scaffold respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种药物结合物。该结合物包括一种基于蛋白质的识别分子（PBRM）和一个具有一个或多个-LD-D的聚合物支架，其中PBRM通过Lp连接到聚合物支架上，聚合物支架包括具有四个或更多—OH基团的线性、分支或环状聚合物。每个D的出现都是独立的，具有分子量<5 kDa的治疗剂。LD和Lp是连接治疗剂和PBRM到聚合物支架的连接剂。还公开了用于与PBRM结合形成聚合物-药物-PBRM结合物的聚合物支架，包括结合物的组成，其制备方法以及使用结合物或其组成物治疗各种疾病的方法。
• PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Santolecan Pharmaceuticals LLC

  公开号：EP3812376A1

  公开（公告）日：2021-04-28

  The present invention pertains to a group of taxane-lipid-polysaccharide dual conjugates of the Formula I, a process for the preparation thereof, uses thereof, and pharmaceutical compositions comprising the same. The invention also relates to a series of intermediates for the preparation of taxane-lipid-polysaccharide dual conjugates, a process for their preparation, and their use as drug delivery vehicles.

  本发明涉及一组式 I 的紫杉烷-脂质-多糖双共轭物、其制备工艺、其用途以及由其组成的药物组合物。本发明还涉及一系列用于制备类固醇-脂质-多糖双共轭物的中间体、其制备工艺及其作为给药载体的用途。
• SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES
  申请人：NOVARTIS AG

  公开号：EP2953976B1

  公开（公告）日：2021-03-24
• US8808679B2
  申请人：——

  公开号：US8808679B2

  公开（公告）日：2014-08-19